239 related articles for article (PubMed ID: 16877733)
1. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
4. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
7. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
Pursche S; Schleyer E; von Bonin M; Ehninger G; Said SM; Prondzinsky R; Illmer T; Wang Y; Hosius C; Nikolova Z; Bornhäuser M; Dresemann G
Curr Clin Pharmacol; 2008 Sep; 3(3):198-203. PubMed ID: 18781906
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
9. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Nghiemphu PL; Wen PY; Lamborn KR; Drappatz J; Robins HI; Fink K; Malkin MG; Lieberman FS; DeAngelis LM; Torres-Trejo A; Chang SM; Abrey L; Fine HA; Demopoulos A; Lassman AB; Kesari S; Mehta MP; Prados MD; Cloughesy TF;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1422-7. PubMed ID: 20934264
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
13. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Chang SM; Kuhn J; Wen P; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; Cloughesy T; De Angelis L; Razier J; Hess K; Dancey J; Prados MD;
Invest New Drugs; 2004 Nov; 22(4):427-35. PubMed ID: 15292713
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
